USPTO 2015–2025 USPTO PatentsView US Corporation

ZOLL Respicardia, Inc.

USPTO PatentsView assignee record - 13 granted patents across 4 technology areas, active 2021–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY).

13
Total patents granted
4
CPC technology areas
18.1
Avg claims per patent
-
5-year filing velocity

The verdict

ZOLL holds 13 US patents across 4 technology areas, rank #22,075 of 50,000 tracked assignees.

#22,075
of 50,000 US assignees by volume
Top 19%
by Innovation Score (47.0/100)
18.1
avg claims per patent

Portfolio overview

ZOLL Respicardia, Inc. has been granted 13 US utility patents between 2021 and 2025, placing ZOLL Respicardia, Inc. at rank #22,075 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.1 claims per patent with primary concentration in A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY). As a US Corporation, ZOLL Respicardia, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 47.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Historical data spans 2021 through 2025, with 13 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. ZOLL Respicardia, Inc.'s 18.1 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark ZOLL Respicardia, Inc. against peers pursuing similar technology classes.

How does ZOLL compare?

Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀

patents

What this shows ZOLL holds 13 patents, placing it at rank #22,075 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView, granted utility patents As of 2015–2025

ZOLL's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

47 Top 19% higher than 81% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2025

012345 2021202220242025 4
USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table
ZOLL Respicardia, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2021 1 7.7%
2022 4 30.8%
2024 4 30.8%
2025 4 30.8%

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Standard

Where it ranks

Overall rank by patents

#22,075

Across all tracked assignees

Innovation Score

47.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does ZOLL Respicardia, Inc. hold?
ZOLL Respicardia, Inc. holds 13 US granted patents filed between 2021 and 2025, spanning 4 technology areas.
What is ZOLL Respicardia, Inc.'s Innovation Score?
ZOLL Respicardia, Inc. has an Innovation Score of 47.0 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does ZOLL Respicardia, Inc. focus on?
ZOLL Respicardia, Inc.'s top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY) with 13 patents. The company has filed patents in 4 CPC subclasses total.
Is ZOLL Respicardia, Inc.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for ZOLL Respicardia, Inc..
What does claim depth mean for ZOLL Respicardia, Inc.'s patents?
ZOLL Respicardia, Inc.'s patents average 18.1 claims each. This falls within the standard range, providing solid legal coverage.
How is the ZOLL Respicardia, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Guides to patent portfolio analysis

How to use this portfolio

ZOLL's 13 grants land it in the top 19% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - ZOLL ranks #22,075 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61N - see who else leads that technology area. A61N leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.